2012
Authors: Bastiaans DET, Forcat S, Lyall HEG, Cressey TR, Chalermpantmetagul S, Saïdi Y, Noguera T, Fortuny C, Compagnucci A, Bleier J, Giaquinto C, Colbers EP, Burger DM.
2012
Authors: Ramos J., Melvin D, Medin G, Compagnucci A, Bleier J, Boscolo V, Barclay L, Ory S, Giaquinto C, Gibb D. on behalf of the PENTA Steering Committee.
2012
Authors: Antinori A., Marcotullio S., Ammassari A., Andreoni M., Angarano G., Armignacco O., Carosi G., Cinque P., d’Arminio Monforte A., Di Perri G., Ensoli B., Florida M.,
2012
Authors: Mbisa JL, Hue S, Buckton AJ, et al.
Published in: AIDS Res Hum Retroviruses. 2012;28(9):1161-1166
Abstract In the late 1980s an HIV-1 epidemic emerged in Romania that was dominated by subtype F1.
2012
Authors: D Bastiaans, S. Forcat, H.E.G. Lyall, T.R. Cressey, S. Chalermpantmetagul, Y. Saïdi, H.J. Scherpbier, A. Warris, A. Compagnucci, C. Giaquinto, E.P. Colbers, D.M. Burger on behalf of PENTA KONCERT Study Group.
2012
Authors: Goetghebuer T, Le Chenadec J, Haelterman E, et al.
Published in: Clinical Infectious Diseases 2012; 54(6): 878-881
Abstract The clinical benefit of antiretroviral therapy in infants is established.
2011
Authors: Lewis J, Walker AS, Castro H, et al.
Published in: J Infect Dis. 2011;205(4):548-556
Background Effective therapies and reduced AIDS-related morbidity and mortality have shifted the focus in pediatric human immunodeficiency virus (HIV) from minimizing short-term disease progression to maintaining optimal long-term health.
2011
Authors: The European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord.
Published in: AIDS 2011; 25(18): 2279-2287
Background Durable and tolerable first-line antiretroviral therapy (ART) regimens are needed for HIV-infected infants who may need life-long treatment.
2011
Authors: Colbers A, Taylor G, Moltó J, Ivanovic J, Taylor G, Branco T, Wyen C, van der Ende I, Gomes da Silva H, Burger D; on behalf of the PANNA network
Published: 12th International Workshop on Clinical Pharmacology of HIV Therapy,
2011
Authors: Compagnucci A. on behalf of the PENTA Steering Committee
Published in: 3rd HIV Paediatric Workshop Rome 15-16 July 2011.
2011
Authors: Wittkop L, Günthard HF, de Wolf F, et al. EuroCoord-CHAIN study group.
Published in: Lancet Infectious Diseases 2011; 11(5): 363-71
Background The effect of transmitted drug resistance (TDR) on first-line combination antiretroviral therapy (cART) for HIV-1 needs further study to inform choice of optimum drug regimens.
2011
Authors: Castro H, Judd A, Gibb DM, et al. Pursuing Later Treatment Options II (PLATO II) project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).
2011
Authors: The PENPACT-1 (PENTA 9 / PACTG 390) Study Team.
Published in: Lancet Infectious Diseases. April: 2011, 273-283
Background Children with HIV will be on antiretroviral therapy (ART) longer than adults,
2010
Authors: Paediatric European Network for Treatment of AIDS (PENTA)
Published in: Antivir Ther. 2010;15(3):297-305.
Background Once-daily dosing of abacavir and lamivudine has been approved for adults,
2010
Authors: Cella M, Gorter de Vries F, Burger D, Danhof M, Della Pasqua O.
Published in: Clinical Pharmacology and Therapeutics, 2010, 87(3):294-302.
2010
Authors: Sefe D, Klein N, Mosconi I, Ricci E, Castro, H (nee Green), Jacobsen M, Bernardi S, Pillay D, Gibb DM, and De Rossi A, on behalf of the PENTA Steering Committee
Published in: 17th Conference on Retroviruses and Opportunistic Infections,
2010
PENTA and IMPAACT: A phase II/III randomised, open-label trial of combination antiretroviral regimens and treatment-switching strategies in HIV-1-infected antiretroviral naïve children
Published in: XVIII International AIDS Conference,
2010
Authors: Lodwick R, Costagliola D, Reiss P, et al. Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).
2010
Authors: Paediatric European Network for Treatment of AIDS.
Published in: AIDS. 2010;24(2):231-241.
Objective To evaluate clinical,
2009
Authors: Jacqz-Aigrain, Farrelly L, Compagnucci A, Harrison L, Zhao W, Hamadache D, Welch S, Wintergerst U, Firtion G, Burger D
Published in: CROI 2009.
2009
Authors: Zhao W, Farrelly L, Compagnucci A, Harrison L, Jacqz-Aigrain E, Hamadache D, Welch S, Wintergerst U, Burger D on behalf of the PENTA Trial Steering Committee .
2009
Authors: Harrison L, Hamadache D, Bunupuradah T, Mazza A, Ramos Amador JT, Flynn J, Rampon O, Mellado Pena MJ, Floret D, Marczynska M, Puga A, Farrelly L,
2009
Authors: Goetghebuer T, Haelterman E, Le Chenadec J, et al. for the European infant collaboration group.
Published in: AIDS 2009;23:597-604
Objective: In the absence of treatment,
2008
Authors: Gibb DM, Compagnucci A, Green H, Lallemant M, et al.
Published in: Journal of the International AIDS Society 2008, 11(Suppl 1):O21 (10 November 2008)
2008
Authors: Cressey TR, Green H, Khoo S, Treluyer J-M, Compagnucci A, Saidi Y, Lallement M, Gibb DM, Burger D.
Published in: Clin Infect Dis 2008.
2007
Authors: Compagnucci A, Saïdi Y, Harper L, Blanche S, Gabiano C, de José Gomez I, Notheis G, Gibb DM, Giaquinto C and Faye A for the PENTA 7 committees
Published in: 14th Conference on Retroviruses and Opportunistic Infections,
2007
Authors: Gibb DM, Green H, Saidi Y, et al; on behalf of PENTA 5.
Published in: AIDS.2007;21(8):947-955
Objective To describe the long-term efficacy over 5 years of regimens including combinations of abacavir,
2006
Authors: Lallemant M, Burger D, Lyall H, Buck L, Compagnucci A, Ramos Amador J.T, Mellado Pena M, Fregonese F, Campbell S, Rampon O, Castelli-Gattinara G, Cressey, Khoo S,
2006
Authors: LeProvost M, Green H, Flynn J, et al; on behalf of the PENTA 13 study group.
Published in: Pediatr Infect Dis J.
2006
Authors: Aboulker J-P, Babiker A, Bacheler L, et al. On behalf of the PENTA 8 study group
Published in: Antivir Ther. 2006;11(7):857-867
Objective To evaluate the longer-term utility of genotypic resistance testing in HIV-1-infected children with virological failure.
2005
Authors: Giaquinto C, Green H, De Rossi A, et al. On behalf of the PENTA 8 study group.
Published in: 3rd IAS Conference on HIV Pathogenesis and Treatment,
2005
Authors: LeProvost M, Green H, Flynn J, et al: on behalf of the PENTA 13 study group.
Published in: 3rd IAS Conference on HIV Pathogenesis and Treatment,
2005
Authors: Compagnucci A, Saïdi Y, Gibb DM, Rampon O, Ramos Amador JT, Feiterna Sperling C, Reliquet V, Giaquinto C, Navarro ML, Girard S, Harper L, Burger D,
2005
Authors: Bergshoeff A, Burger D, Verweij C, et al; on behalf of the PENTA 13 study group
Published in: Antivir Ther. 2005;
2005
Authors: De Rossi A, Walker AS, De Forni D, Klein N, Dibb DM. Paediatric European Network for Treatment of AIDS (PENTA)
Published in: Antivir Ther.
2004
Authors: Gibb DM, Melvin A, Compagnucci A, McKinney R, Tudor-Williams G, Walker AS, Harper L, Hodge J, Powell C, Green H, Saïdi Y, Ortiz AA, Toye M,
2004
Authors: Compagnucci A, Saïdi Y, Harper L, Navarro ML, Girard S, Walker AS, Debré M, Gibb DM, Rampon O, Lachassine E, Schmitz T, Giaquinto C, Aboulker JP,
2004
Authors: Aboulker JP, Babiker A, Chaix ML, et al; Paediatric European Network for Treatment of AIDS.
Published in: AIDS. 2004.23;18(2):237-45
2004
Authors: Sharland M, Blanche S, Castelli G, Ramos J, Gibb DM for the PENTA Steering Committee.
Published in: HIV Med 2004;
2004
Authors: Writing Committee (alphabetical): Aboulker J-P, Babiker A, Chaix ML, Compagnucci A, Darbyshire JH, Debré M, Faye A, Giaquinto C, Gibb DM, Harper L, Saidi Y, Walker AS
Published in: AIDS 2004;18 (2):237-245
Objective To assess the feasibility and impact of highly active antiretroviral therapy (HAART) started in vertically HIV-1-infected infants less than 3 months of age.
2004
Authors: Burger DM, Bergshoeff A, de Groot R, et al; on behalf of the PENTA 5 study group.
Published in: J Paediatr 2004;
2004
Authors: Lanier ER, Givens N, Stone C, et al.
Published in: HIV Med. 2004;5(6):394-399
Objectives Abacavir (ABC) selects for four mutations (K65R,
2004
Authors: Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, LeProvost M, Walker AS, Novelli V, Lyall H, Gibb DM.
Published in: 11th Conference of Retroviruses and Opportunistic Infections,
2003
Authors: Compagnucci A, Saidi Y, Faye A, et al.
Published in: 2nd IAS Conference on HIV Pathogenesis and Treatment, 13-16 July Paris.
2003
Authors: Litalien C, Faye A, Compagnucci A, Giaquinto C, Harper L, Gibb DM, Jacqz-Aigrain E for PENTA.
Published in: Pediatr Inf Dis J 2003;
2003
Authors: Gibb DM, Giaquinto C, Walker AS, Harper L, Compagnucci A, Saidi Y, Moulinier C, Aboulker JP, Babiker AG, Debré M, Darbyshire JH on behalf of the PENTA 5 Executive Committee
Published: 10th Conference on Retroviruses and Opportunistic Infections February 10th –
2003
Authors: De Rossi A, Walker AS, De Forni D, Gibb DM on behalf of PENTA.
Published in: 10th Conference on Retroviruses and Opportunistic Infections February 10th –
2003
Author: Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H. Paediatric European Network for Treatment of AIDS Steering Committee.
Published in: Pediatr Infect Dis J.
2002
Authors: Ait-Khaled M, Lanier R, Richards N, Stone C, Griffin P, Gibb DM, Walker AS, Craig C, Loeliger E, Tisdale M
Published in: 2002 International Meeting of the Institute of Human Virology,
2002
Authors: Giacomet V, Gibb DM, Goodall R, McGee L, Walker AS, Giaquinto C.
Published in: XIV World AIDS Conference, 7th-12th July 2002,